PJA1

Across TCGA pan-cancer cohorts, PJA1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PJA1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher PJA1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PJA1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, CESC, and UCEC are the cancer types where PJA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
CESC	OS	Median	II,III,IV	0.121	0.829	<.001	36	view →
UCEC	DFS	Median	III,IV	0.873	0.527	.030	18	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	9	view →
STAD	DFS	Median	All	0.211	0.709	.015	6	view →
COAD	DFS	Median	II,III,IV	0.140	0.743	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PJA1–CHOL (OS)

Open the CHOL breakdown →